Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
After attending the University of Arizona where he studied Molecular and Cellular Biology and English Literature, Dr. Ng attended Harvard Medical School where he received an MD, PhD. His graduate work was performed with Katia Georgopoulos in the Department of Immunology where he studied genetic regulation in lymphocyte development mediated by the genes Ikaros and Mi-2beta. He completed his clinical training with a residency in Internal Medicine at Brigham and Women’s Hospital followed by a fellowship with the Dana-Farber/Partners Cancer Center program in Hematology and Oncology. He is an attending physician in the Lymphoma Program of the Division of Hematologic Malignancies at Dana-Farber. Dr. Ng has an active research interest in the biology of T-cell lymphomas and is currently pursuing this work in the laboratory of David Weinstock at DFCI. Ultimately, the aims of his clinical and research efforts are to help develop novel therapies that improve outcomes for patients afflicted with T-cell Lymphoma.
Samuel Ng, MD, PhD, treats patients with non-Hodgkin lymphoma, Hodgkin lymphoma and chronic lymphocytic leukemia (CLL). Taking a very transparent approach to patient care, Dr. Ng involves patients and their families in each decision in the treatment journey. Learn more about the Adult Lymphoma program at: http://www.dana-farber.org/lymphoma-program/
Dana-Farber Cancer Institute450 Brookline AvenueBoston, MA 02215Get Directions